PA
HBI

PharVision Advisers’s Hanesbrands HBI Stock Holding History

PharVision Advisers’s Portfolio HBI Stock Details HBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,931
Closed -$97.7K – 342
2025
Q1 		$97.7K Sell
16,931
-38,699
-70% -$271K 0.14% 248
2024
Q4 		$453K Buy
+55,630
New +$438K 0.38% 59

Other funds holding HBI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LC
Loews Corp New York $11.9B AUM 8.99% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PharVision Advisers's HBI Position: Q2 2025 in Review

PharVision Advisers sold out of Hanesbrands (HBI) in Q2 2025, closing a stake of 16,931 shares — an estimated $97.7K sold.

PharVision Advisers first reported a position in HBI in Q4 2024 and held it in 2 quarters. The position peaked at $453K in Q4 2024. 387 funds tracked by Wall St. Rank hold HBI as of Q2 2025.

  • PharVision Advisers reported no remaining Hanesbrands position as of Q2 2025 after selling out during the quarter.
  • PharVision Advisers sold 16,931 Hanesbrands shares in Q2 2025, an estimated $97.7K.
  • PharVision Advisers first reported a position in Hanesbrands in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's Hanesbrands position peaked at $453K in Q4 2024.
  • 387 funds tracked by Wall St. Rank held Hanesbrands as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.